Evaluating Rivaroxaban for Blood Coagulation
Author Information
Author(s): Burghaus Rolf, Coboeken Katrin, Gaub Thomas, Kuepfer Lars, Sensse Anke, Siegmund Hans-Ulrich, Weiss Wolfgang, Mueck Wolfgang, Lippert Joerg
Primary Institution: Bayer Schering Pharma AG
Hypothesis
This study aimed to use a computer model to compare the mechanism of action of rivaroxaban with that of warfarin and to evaluate the efficacy and safety of different rivaroxaban doses.
Conclusion
Rivaroxaban shows a favorable sensitivity for tissue factor concentration inducing clotting and has a broad therapeutic window.
Supporting Evidence
- Rivaroxaban is approved for preventing blood clots in patients undergoing hip or knee surgery.
- The model used in the study incorporates both intrinsic and extrinsic pathways of coagulation.
- Rivaroxaban's mechanism of action is different from that of traditional anticoagulants.
Takeaway
Rivaroxaban is a new blood thinner that works differently than older ones like warfarin, and it has a good safety range for use.
Methodology
A computer model for blood coagulation was developed to simulate the effects of rivaroxaban and other anticoagulants under various conditions.
Potential Biases
All authors are employees of Bayer AG, which may introduce bias in the study.
Limitations
The model only focused on the onset of coagulation and did not include fibrinolysis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website